These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578 [TBL] [Abstract][Full Text] [Related]
4. Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E Yoshino K; Hosooka T; Shinohara M; Aoki C; Hosokawa Y; Imamori M; Ogawa W Biochem Biophys Res Commun; 2021 Jun; 557():62-68. PubMed ID: 33862461 [TBL] [Abstract][Full Text] [Related]
5. Celecoxib ameliorates non-alcoholic steatohepatitis in type 2 diabetic rats via suppression of the non-canonical Wnt signaling pathway expression. Tian F; Zhang YJ; Li Y; Xie Y PLoS One; 2014; 9(1):e83819. PubMed ID: 24404139 [TBL] [Abstract][Full Text] [Related]
6. Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats. Kimura Y; Kuno A; Tanno M; Sato T; Ohno K; Shibata S; Nakata K; Sugawara H; Abe K; Igaki Y; Yano T; Miki T; Miura T J Diabetes Investig; 2019 Jul; 10(4):933-946. PubMed ID: 30663266 [TBL] [Abstract][Full Text] [Related]
7. "2-(4-Fluorobenzamido)-4-methylthiazole-5-carboxylic acid" a novel thiazole compound, ameliorates insulin sensitivity and hyperlipidaemia in streptozotocin-induced diabetic rats: Plausible role of inflammatory and oxidative stress markers. Paudel YN; Ali MR; Adil M; Bawa S; Sharma M Biomed Pharmacother; 2017 Nov; 95():1232-1241. PubMed ID: 28938514 [TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid prevents the hepatic changes associated with high fat diet in rats; the potential role of mevalonic acid pathway in nonalcoholic steatohepatitis. Mohamed RH; Tarek M; Hamam GG; Ezzat SF Eur J Pharmacol; 2019 Sep; 858():172469. PubMed ID: 31233751 [TBL] [Abstract][Full Text] [Related]
9. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. Ozutsumi T; Namisaki T; Shimozato N; Kaji K; Tsuji Y; Kaya D; Fujinaga Y; Furukawa M; Nakanishi K; Sato S; Sawada Y; Saikawa S; Kitagawa K; Takaya H; Kawaratani H; Kitade M; Moriya K; Noguchi R; Akahane T; Mitoro A; Yoshiji H Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245205 [TBL] [Abstract][Full Text] [Related]
10. Carnosine decreased oxidation and glycation products in serum and liver of high-fat diet and low-dose streptozotocin-induced diabetic rats. Aydın AF; Bingül İ; Küçükgergin C; Doğan-Ekici I; Doğru Abbasoğlu S; Uysal M Int J Exp Pathol; 2017 Oct; 98(5):278-288. PubMed ID: 29205589 [TBL] [Abstract][Full Text] [Related]
11. Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats. Yang ZR; Wang HF; Zuo TC; Guan LL; Dai N BMC Pharmacol Toxicol; 2016 Apr; 17():16. PubMed ID: 27075663 [TBL] [Abstract][Full Text] [Related]
13. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model. Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868 [TBL] [Abstract][Full Text] [Related]
14. Antidiabetic effects of nerolidol through promoting insulin receptor signaling in high-fat diet and low dose streptozotocin-induced type 2 diabetic rats. Jiang N; Zhang Y Hum Exp Toxicol; 2022; 41():9603271221126487. PubMed ID: 36169646 [TBL] [Abstract][Full Text] [Related]
15. Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy. Xu Z; Hu W; Wang B; Xu T; Wang J; Wei D Yonsei Med J; 2022 Jul; 63(7):619-631. PubMed ID: 35748073 [TBL] [Abstract][Full Text] [Related]
16. Sodium acetate-mediated inhibition of histone deacetylase alleviates hepatic lipid dysregulation and its accompanied injury in streptozotocin-nicotinamide-induced diabetic rats. Olaniyi KS; Amusa OA Biomed Pharmacother; 2020 Aug; 128():110226. PubMed ID: 32460191 [TBL] [Abstract][Full Text] [Related]
17. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus. Woods TC; Satou R; Miyata K; Katsurada A; Dugas CM; Klingenberg NC; Fonseca VA; Navar LG Am J Nephrol; 2019; 49(4):331-342. PubMed ID: 30921791 [TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation. Hazem RM; Ibrahim AZ; Ali DA; Moustafa YM Int Immunopharmacol; 2022 Mar; 104():108503. PubMed ID: 34998036 [TBL] [Abstract][Full Text] [Related]
19. Ellagic Acid Alleviates Hepatic Oxidative Stress and Insulin Resistance in Diabetic Female Rats. Polce SA; Burke C; França LM; Kramer B; de Andrade Paes AM; Carrillo-Sepulveda MA Nutrients; 2018 Apr; 10(5):. PubMed ID: 29693586 [TBL] [Abstract][Full Text] [Related]
20. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Sha S; Polidori D; Heise T; Natarajan J; Farrell K; Wang SS; Sica D; Rothenberg P; Plum-Mörschel L Diabetes Obes Metab; 2014 Nov; 16(11):1087-95. PubMed ID: 24939043 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]